[go: up one dir, main page]

TN2010000251A1 - N-acetyl-dl-leucine medicament neuro et retino protecteur - Google Patents

N-acetyl-dl-leucine medicament neuro et retino protecteur

Info

Publication number
TN2010000251A1
TN2010000251A1 TN2010000251A TN2010000251A TN2010000251A1 TN 2010000251 A1 TN2010000251 A1 TN 2010000251A1 TN 2010000251 A TN2010000251 A TN 2010000251A TN 2010000251 A TN2010000251 A TN 2010000251A TN 2010000251 A1 TN2010000251 A1 TN 2010000251A1
Authority
TN
Tunisia
Prior art keywords
acetyl
retino
neuro
protector
leucine
Prior art date
Application number
TN2010000251A
Other languages
English (en)
Inventor
Rekik Raouf
Original Assignee
Rekik Raouf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rekik Raouf filed Critical Rekik Raouf
Priority to TN2010000251A priority Critical patent/TN2010000251A1/fr
Priority to ES11726946.4T priority patent/ES2686295T3/es
Priority to RU2012151575/15A priority patent/RU2598339C2/ru
Priority to PCT/IB2011/000965 priority patent/WO2011151685A1/fr
Priority to EP11726946.4A priority patent/EP2575793B1/fr
Priority to CA2801145A priority patent/CA2801145C/fr
Priority to JP2013512993A priority patent/JP5959507B2/ja
Priority to PL11726946T priority patent/PL2575793T3/pl
Priority to AU2011259997A priority patent/AU2011259997B2/en
Priority to US13/701,300 priority patent/US9155719B2/en
Priority to CN2011800376103A priority patent/CN103079550A/zh
Publication of TN2010000251A1 publication Critical patent/TN2010000251A1/fr
Priority to ZA2012/09595A priority patent/ZA201209595B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un medicament dont Ie principe actif est la N - ACETYL - DL¬LEUCINE. II est appliqué au traitement des dystrophies retiniennes héréditaires ; neuropathie glaucomateuse, dégénérescence maculaire, myopie, presbytie, hypermetropie, astigmatisme, toutes les affections ophtalmologiques induisant une baisse de la fonction visuelle et en fin la baisse physiologique de la vision liée à l'age.
TN2010000251A 2010-06-03 2010-06-03 N-acetyl-dl-leucine medicament neuro et retino protecteur TN2010000251A1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
TN2010000251A TN2010000251A1 (fr) 2010-06-03 2010-06-03 N-acetyl-dl-leucine medicament neuro et retino protecteur
CA2801145A CA2801145C (fr) 2010-06-03 2011-05-06 N-acetyl-dl-leucine, medicament neuroprotecteur et retinoprotecteur
RU2012151575/15A RU2598339C2 (ru) 2010-06-03 2011-05-06 Нейропротекторное и ретинопротекторное средство n-ацетил-dl-лейцин
PCT/IB2011/000965 WO2011151685A1 (fr) 2010-06-03 2011-05-06 N-acétyl-dl-leucine, médicament neuroprotecteur et rétinoprotecteur
EP11726946.4A EP2575793B1 (fr) 2010-06-03 2011-05-06 N-acétyl-dl-leucine, médicament neuroprotecteur et rétinoprotecteur
ES11726946.4T ES2686295T3 (es) 2010-06-03 2011-05-06 N-Acetil-DL-leucina, medicamento neuroprotector y retinoprotector
JP2013512993A JP5959507B2 (ja) 2010-06-03 2011-05-06 神経保護性および網膜保護性医薬であるｎ−アセチル−ｄｌ−ロイシン
PL11726946T PL2575793T3 (pl) 2010-06-03 2011-05-06 N-acetylo-dl-leucyna, środek neuroprotekcyjny i chroniący siatkówkę
AU2011259997A AU2011259997B2 (en) 2010-06-03 2011-05-06 N-acetyl-DL-leucine, neuroprotective and retinoprotective medicament
US13/701,300 US9155719B2 (en) 2010-06-03 2011-05-06 N-acetyl-DL-leucine, neuroprotective and retinoprotective medicament
CN2011800376103A CN103079550A (zh) 2010-06-03 2011-05-06 N-乙酰-dl-亮氨酸，神经保护性和视网膜保护性药物
ZA2012/09595A ZA201209595B (en) 2010-06-03 2012-12-18 N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TN2010000251A TN2010000251A1 (fr) 2010-06-03 2010-06-03 N-acetyl-dl-leucine medicament neuro et retino protecteur

Publications (1)

Publication Number Publication Date
TN2010000251A1 true TN2010000251A1 (fr) 2011-11-11

Family

ID=54695902

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2010000251A TN2010000251A1 (fr) 2010-06-03 2010-06-03 N-acetyl-dl-leucine medicament neuro et retino protecteur

Country Status (12)

Country Link
US (1) US9155719B2 (fr)
EP (1) EP2575793B1 (fr)
JP (1) JP5959507B2 (fr)
CN (1) CN103079550A (fr)
AU (1) AU2011259997B2 (fr)
CA (1) CA2801145C (fr)
ES (1) ES2686295T3 (fr)
PL (1) PL2575793T3 (fr)
RU (1) RU2598339C2 (fr)
TN (1) TN2010000251A1 (fr)
WO (1) WO2011151685A1 (fr)
ZA (1) ZA201209595B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014001889A1 (fr) * 2012-06-29 2014-01-03 Raouf Rekik Inhibiteurs de l'enzyme de conversion de l'angiotensine destinés au traitement d'une neuropathie optique ou d'une atrophie optique congénitale
JP6764233B2 (ja) * 2015-02-10 2020-09-30 国立大学法人京都大学 眼疾患処置薬
BR112018071547A2 (pt) * 2016-04-19 2019-03-06 Intrabio Ltd acetil-leucina ou um sal farmaceuticamente aceitável desta
TN2016000259A1 (en) * 2016-06-27 2017-10-06 Rekik Raouf Salbutamol (albuterol) eye protective medicament.
TN2019000033A1 (fr) * 2016-08-11 2020-07-15 Intrabio Ltd Agents thérapeutiques pour maladies neurodégénératives
SI3482754T1 (sl) * 2016-08-11 2021-04-30 Intrabio Ltd Farmacevtski sestavki in uporabe usmerjene v motnje lizosomalnega shranjevanja
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
AU2018351709B2 (en) * 2017-10-18 2024-01-04 Intrabio Limited Therapeutic agents for neurodegenerative diseases
CN111712239A (zh) * 2018-02-15 2020-09-25 内在生物技术有限公司 治疗不宁腿综合征的治疗剂
CN113164421A (zh) * 2018-12-18 2021-07-23 参天制药株式会社 含有4-苯基丁酸的老视的治疗或预防剂
JP7555346B2 (ja) * 2019-03-02 2024-09-24 イントラビオ エルティーディー 疾患の治療のためのロイシン、アセチルロイシン、及び関連類似体
WO2022157808A1 (fr) * 2021-01-23 2022-07-28 Celagenex Research (India) Pvt. Ltd. Compositions nutritionnelles synergiques pour le traitement de maladies neurodégénératives associées au vestibule

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60255722A (ja) * 1984-05-30 1985-12-17 Otsuka Pharmaceut Factory Inc 糖尿病用アミノ酸輸液
US4837219A (en) * 1987-11-05 1989-06-06 Jeffrey Hutterer Medication for Alzheimer's disease
DE3811177A1 (de) * 1988-03-31 1989-10-19 Ernst Hajek Verwendung von (alpha)-amino-isocapronsaeure (leucin) als wirkstoff zur bekaempfung der hiv-erkrankung aids
JPH0368514A (ja) * 1989-08-09 1991-03-25 Morishita Pharmaceut Co Ltd 癌用アミノ酸製剤
DE4243362A1 (de) * 1992-12-21 1994-06-23 Ulrich Dr Med Kuebler Mittel zur Behandlung von Hauttrockenheit, des Neuroendokriniums und Immunsystems
US5596011A (en) * 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
FR2749512B1 (fr) * 1996-06-10 1999-08-13 Pf Medicament Utilisation de l'acetyl dl leucine pour le traitement des tremblements
JPH10323183A (ja) * 1997-03-25 1998-12-08 Otsuka Pharmaceut Factory Inc 細胞保護液
FR2815541B1 (fr) * 2000-10-24 2008-02-29 Lipha Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique
JP3341769B1 (ja) * 2002-01-25 2002-11-05 味の素株式会社 分岐鎖アミノ酸含有チュアブル剤
WO2004028536A1 (fr) * 2002-09-30 2004-04-08 Babizhayev Mark A Methode de traitement topique de maladies de l'oeil, composition et dispositif conçus pour ce traitement
AU2003296176A1 (en) * 2002-12-26 2004-07-22 Ajinomoto Co., Inc. Inhibitor for liver cancer onset and progress
JP4528925B2 (ja) * 2003-05-30 2010-08-25 独立行政法人理化学研究所 アミノ酸組成物及び補液
WO2005023368A1 (fr) * 2003-09-04 2005-03-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Prophylaxie et traitement d'infections par des bacteries de la famille des chlamydiaceae au moyen d'acides amines, tels que la leucine ou la methionine
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
JP2007039367A (ja) * 2005-08-02 2007-02-15 Kyoto Univ 細胞の分化を促進する組成物およびその利用
JP2008024675A (ja) * 2006-07-25 2008-02-07 Kowa Co 内服液剤組成物
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
EP2098124A1 (fr) * 2008-03-03 2009-09-09 Nestec S.A. Gel de glucide
WO2010065723A1 (fr) * 2008-12-03 2010-06-10 President And Fellows Of Harvard College Procédés pour prolonger la viabilité de cônes en utilisant des modulateurs de la cible mammalienne de la voie de la rapamycine (mtor)
WO2010137944A1 (fr) * 2009-05-27 2010-12-02 N.V. Nutricia Traitement de l'hypercalcémie
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs

Also Published As

Publication number Publication date
AU2011259997A1 (en) 2013-01-24
PL2575793T3 (pl) 2019-04-30
EP2575793A1 (fr) 2013-04-10
CN103079550A (zh) 2013-05-01
AU2011259997A9 (en) 2013-05-02
RU2598339C2 (ru) 2016-09-20
AU2011259997B2 (en) 2016-05-05
JP5959507B2 (ja) 2016-08-02
CA2801145C (fr) 2019-08-06
ZA201209595B (en) 2014-03-26
ES2686295T3 (es) 2018-10-17
AU2011259997A2 (en) 2013-01-31
JP2013527222A (ja) 2013-06-27
US9155719B2 (en) 2015-10-13
EP2575793B1 (fr) 2018-06-06
CA2801145A1 (fr) 2011-12-08
AU2011259997A8 (en) 2013-05-02
WO2011151685A8 (fr) 2013-01-10
US20130142888A1 (en) 2013-06-06
WO2011151685A1 (fr) 2011-12-08
RU2012151575A (ru) 2014-07-20

Similar Documents

Publication Publication Date Title
TN2010000251A1 (fr) N-acetyl-dl-leucine medicament neuro et retino protecteur
Lalu et al. Novel nanosystems for the treatment of ocular inflammation: Current paradigms and future research directions
MX2010003774A (es) Formulaciones oftalmicas acuosas.
KR102614858B1 (ko) 안검염 치료에 사용되는 약제학적 조성물
JP6981694B2 (ja) 選択された抗コリン作用性双性イオンの使用
MY173699A (en) Novel compounds for the treatment of diseases associated with amyloid of amyloid-like proteins
Bagnis et al. Antiglaucoma drugs: The role of preservative-free formulations
ES2770410T3 (es) Combinación de ácido fólico - ramiprilo: composiciones oftalmológicas celuloprotectoras, neuroprotectoras y retinoprotectoras
JP2020531511A5 (fr)
AU2011282679A1 (en) Preservative free bimatoprost solutions
RU2017111579A (ru) Способы лечения и предотвращения заболеваний глаз, расстройств и патологических состояний меланином и аналогами, предшественниками и производными меланина
PH12020550722A1 (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
Garcia-Catalan et al. Charles Bonnet syndrome precipitated by brimonidine
CN117320726A (zh) 抑制近视用滴眼剂
RU2012120096A (ru) Офтальмологические препараты на основе bdnf (нейротрофического фактора головного мозга) и их применение
BRPI0411427A (pt) formulações de agentes antiinflamatórios não-esteróides para o tratamento de angiogênese ocular patológica
Drozdova et al. Individual approach to the treatment of complicated forms of blepharitis: from theory to practice
Shechtman Is Wearing a Mask Causing Your Dry Eyes
Taylor et al. Ernest Iakovlev, Radwan Almousa
Faustino Various toxicities: case report
Kramer Therapy options based on DED severity
Sheikh Cosmetic Contact lens Induced Corneal Ulcers
Gualtieri Maculopathy: case report
Sacchi Pseudophakic cystoid macular oedema with serous retinal detachment: case report
Ha Ocular hypertension: case report